{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:07:12Z","timestamp":1768435632628,"version":"3.49.0"},"reference-count":44,"publisher":"BMJ","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Educ Pract Ed"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p>Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatic disease with significant long-term morbidity and mortality. Major advances have taken place in recent years in our understanding and the evidence base of JIA.<\/jats:p>\n               <jats:p>The advent of biological therapies has opened a major new era in the medical management of JIA with recent trials published of etanercept, infliximab, adalimumab, abatacept, tocilizumab and anakinra.<\/jats:p>\n               <jats:p>National and international collaborative clinical and research networks are ideally placed to enable future advances in the management of JIA and all paediatric rheumatic disorders.<\/jats:p>\n               <jats:p>This review follows on from Part 1 of a review of recent advances in non-biological therapies in JIA, and focuses on the significant new advances in biological therapies in managing JIA.<\/jats:p>","DOI":"10.1136\/adc.2009.170860","type":"journal-article","created":{"date-parts":[[2009,9,21]],"date-time":"2009-09-21T17:59:26Z","timestamp":1253555966000},"page":"151-156","source":"Crossref","is-referenced-by-count":41,"title":["New advances in the management of juvenile idiopathic arthritis\u20142: The era of biologicals"],"prefix":"10.1136","volume":"94","author":[{"given":"M W","family":"Beresford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E M","family":"Baildam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2009,9,21]]},"reference":[{"key":"2025090701240157000_94.5.151.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2196"},{"key":"2025090701240157000_94.5.151.2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282fa13b4"},{"key":"2025090701240157000_94.5.151.3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0654-6"},{"key":"2025090701240157000_94.5.151.4","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283060778"},{"key":"2025090701240157000_94.5.151.5","first-page":"15","article-title":"Biologic therapies in juvenile idiopathic arthritis: why and for whom?","volume":"32","author":"McCann","year":"2007","journal-title":"Acta Reumatol Port"},{"key":"2025090701240157000_94.5.151.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003163421103"},{"key":"2025090701240157000_94.5.151.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.22838"},{"key":"2025090701240157000_94.5.151.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"2025090701240157000_94.5.151.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60998-8"},{"key":"2025090701240157000_94.5.151.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"2025090701240157000_94.5.151.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.23427"},{"key":"2025090701240157000_94.5.151.12","first-page":"S943","article-title":"Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis (JIA) patients.","volume":"58","author":"Southwood","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025090701240157000_94.5.151.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken242"},{"key":"2025090701240157000_94.5.151.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087411"},{"key":"2025090701240157000_94.5.151.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087593"},{"key":"2025090701240157000_94.5.151.16","first-page":"2481","article-title":"Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.","volume":"34","author":"Vojvodich","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090701240157000_94.5.151.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0563-2"},{"key":"2025090701240157000_94.5.151.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.3.245"},{"key":"2025090701240157000_94.5.151.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.20793"},{"key":"2025090701240157000_94.5.151.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014886"},{"key":"2025090701240157000_94.5.151.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.10885"},{"key":"2025090701240157000_94.5.151.22","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0084"},{"key":"2025090701240157000_94.5.151.23","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F"},{"key":"2025090701240157000_94.5.151.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.20288"},{"key":"2025090701240157000_94.5.151.25","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32825a6a79"},{"key":"2025090701240157000_94.5.151.26","doi-asserted-by":"publisher","DOI":"10.1186\/ar1826"},{"key":"2025090701240157000_94.5.151.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076034"},{"key":"2025090701240157000_94.5.151.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.23437"},{"key":"2025090701240157000_94.5.151.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken030"},{"key":"2025090701240157000_94.5.151.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082859"},{"key":"2025090701240157000_94.5.151.31","first-page":"362","article-title":"Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis.","volume":"32","author":"Foeldvari","year":"2005","journal-title":"J Rheumatol"},{"key":"2025090701240157000_94.5.151.32","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/112067210701700509","article-title":"Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication.","volume":"17","author":"Heiligenhaus","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"2025090701240157000_94.5.151.33","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.6.2.111.4046"},{"key":"2025090701240157000_94.5.151.34","first-page":"2583","article-title":"IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis.","volume":"40","author":"Brito","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025090701240157000_94.5.151.35","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830260510"},{"key":"2025090701240157000_94.5.151.36","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3282f03d42"},{"key":"2025090701240157000_94.5.151.37","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3180318fbc"},{"key":"2025090701240157000_94.5.151.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.04.058"},{"key":"2025090701240157000_94.5.151.39","first-page":"72","article-title":"Update on treatment of arthritis in children: new treatments, new goals.","volume":"64","author":"Lovell","year":"2006","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"2025090701240157000_94.5.151.40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken055"},{"key":"2025090701240157000_94.5.151.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8"},{"key":"2025090701240157000_94.5.151.42","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000130286.54383.ea"},{"key":"2025090701240157000_94.5.151.43","first-page":"33","article-title":"Treating children with arthritis: towards an evidence-based culture.","volume":"72","author":"Feldman","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"2025090701240157000_94.5.151.44","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.113357"}],"container-title":["Archives of disease in childhood - Education &amp; practice edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/adc.2009.170860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:24:07Z","timestamp":1757233447000},"score":1,"resource":{"primary":{"URL":"https:\/\/ep.bmj.com\/lookup\/doi\/10.1136\/adc.2009.170860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,21]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,9,21]]},"published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1136\/adc.2009.170860"],"URL":"https:\/\/doi.org\/10.1136\/adc.2009.170860","relation":{},"ISSN":["1743-0585","1743-0593"],"issn-type":[{"value":"1743-0585","type":"print"},{"value":"1743-0593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,21]]}}}